Genuit Share Discussion Threads

[rambutan2] 05/9/2002 20:12

Dead day, hope its not slipping back into old lack-of-trade habits.

16:05:19   11p   11p   13p   10,000   £1,100   SELL O
14:06:42   12p   11p   13p   5,300   £636     O
12:33:52   11p   11p   13p   8,127   £894   SELL O

[rambutan2] 04/9/2002 20:22

Slowly moving up.

16:26:03   13p           25,000   £3,250   DLY O
14:06:31   11p           100,000   £11,000   DLY O
13:53:11   11p   11p   13p   15,000   £1,650   SELL O
13:39:25   11p   11p   13p   5,050   £556   SELL O
13:07:35   11p           20,000   £2,200   DLY O
13:03:15   12p           50,000   £6,000   DLY O
12:03:24   11.598p   11p   13p   7,500   £870   SELL O
10:27:12   13p   11p   13p   11,500   £1,495   BUY O
09:58:25   12p           25,000   £3,000   DLY O

[rambutan2] 03/9/2002 18:57

Today's trades, nearly all buys with a couple of bigger ones in there.
Not bad on such a rotten day.

16:25:16   13p   10p   13p   11,500   £1,495   BUY O
16:19:38   13p           25,000   £3,250   DLY O
15:47:12   11.5p   10p   13p   10,000   £1,150     O
15:22:39   13p   10p   13p   7,692   £1,000   BUY O
15:21:53   10.5p           38,100   £4,000   DLY O
14:48:27   12p           44,500   £5,340   DLY O
14:45:57   12p           50,000   £6,000   DLY O
13:41:31   11.5p   10p   13p   2,000   £230     O
13:16:18   12p           30,000   £3,600   DLY O
12:32:05   11p   9p   13p   500   £55     O
09:31:59   10.898p   10p   13p   8,000   £872   SELL O

[rambutan2] 03/9/2002 14:26

Generics Group AG - Director Shareholding
RNS Number:6483A
Somehow missed this last night.

On the 2nd September 2002, Professor Gordon Edge, chairman of the Generics Group
AG, informed the company that on the 30th August 2002 he has purchased
additional 222,222 shares of CHF 0.10 each in Generics at 9 pence per share. His
total holding of CHF 0.10 shares now stands at 10, 350, 848 shares.

On the same date, the company was also informed that the James Hay Pension
Trustees Limited, account: Professor Gordon Edge purchased 333,333 shares of CHF
0.10 each in Generics at 9 pence per share on behalf of Professor Gordon Edge.
This transaction represents the entire shareholding of the James Hay Pension
Trustees Limited, account: Professor Gordon Edge in Generics.

[rambutan2] 03/9/2002 12:55

another duplicate!

[rambutan2] 03/9/2002 12:49

Getting back to yesterday's directors' buying, and with regard to the stuff i posted tonight, it is interesting to note that the two who bought were the Catella board members. Rylander is the founder and group CE, and Bjorklund is Controller and Financial Director of Catella. They know that they need to get their baby back on the road! Or perhaps they orders from above!!

[rambutan2] 03/9/2002 12:10

From happier times!

'Levitation legend' achieves 'miraculous' share flotation
JENNY CHAPMAN talks to the charismatic founder of Scientific Generics Prof Gordon Edge.
WE spend the first few minutes talking about nose bleeds. Mr Edge has had such a bad one it had to be cauterized last night.
A pile of tissues sit between us, and I hope I can remember my first aid.
"I'm supposed to go to Sweden this afternoon," he says, and I think of the pressurized aircraft cabin and the affect on noses.
Then we are talking about Scientific Generics -- its miraculous flotation. Miraculous because it bucked the market trend that was severely southerly two weeks' ago, miraculous because Mr Edge says nobody ever really understands SG's business model.
Well, here goes. It has four basic elements, or earning areas, traditional technology consultancy, acquisitions, investment in new companies spun out of SG, and investments in other people's businesses.
It's the model devised by Mr Edge in the 1980s when he left PA Technology to found SG. It's the model that saw SG nine times oversubscribed at the beginning of this month when the company floated on the London Stock Exchange.
Somewhere along the line the 70 fund managers who listened to SG's roadshow presentation got the general drift of that business model, but what's surprising is that only one asked how long Mr Edge planned on remaining with the company.
"How did you feel about that?"
"I feel great about it. I'm happy they didn't ask it because they could see I was committed to the company."
Mr Edge, who is also Prof Edge (currently visiting at Bath), is, even in a time and a place that is legendary in itself, a legend.
I can't resist it, I have to ask about the levitation story, that he could sell it if he had a mind to. It's a story that has been around for decades, probably since the days he was in charge at Cambridge Consultants, certainly in the days he ran PA Technology.
"I tend to spot opportunities before they become clear to other people," he says. "And they tend to be things which people say are not possible. PA was into cellular technology years before anyone else. Generics ran a seminar on the human genome in 1987."
He pauses. "I am genuinely anxious to avoid this hero thing," he says. "Nothing is further from the truth. There have always been lots of people involved, and it has always been very egalitarian."
Of course it has. But if someone has been labelled, for years, with the ability to sell something as up in the air as levitation, what can they expect?
Mr Edge can shun the limelight as much as he likes, it will probably only serve to perpetuate the legend. Duncan Hine, a big company man, was brought in to take SG public, but everyone still wants to talk to Mr Edge, who never had any doubts about his business model, knew from the beginning that it would be a big success, and has no worries about the future.
This month's flotation made him £27 million richer, albeit on paper at the moment; but such has been the demand for SG's shares the mysterious "greenshoe" has already been brought into play, a devise that checks excessive demand by releasing more shares from the principal shareholder, in SG's case, Catella, the Swedish knowledge management company that's partly owned by Ikea.
The Swedish connection goes back to the days when Mr Edge was setting up SG and a Swedish friend, a director of Catella, was keen to buy in.
This was hardly surprising, given the Edge track record, headhunted from CCL to start a technology division for PA, which, by the time he left had contributed largely to a hike in turnover for the group from £30 million to £300 million.
And it all started with crystal sets. Age seven the boy Gordon was building his first radio, even earlier he was putting together his first cinema projector: "I've always been fascinated by cinema and used to go down to the local one and plead to be given the cut-outs of film which I then projected using my aunt's glasses."
These days, in his home just outside Cambridge, he has his own private cinema: "A very selfish affair," he says, "only seven or eight seats." The most recent film? "'The End of the Affair', both versions."
He hasn't read the book, but when it comes to books, he says Pepys is his favourite, and he goes into a kind of reverie describing a passage all about wife-beating. Surely not? He's much too nice. We must talk about the business. It's doubling in size. The bulldozers are ploughing up the fields beyond Harston Mill as we speak. Headcount will rise from 230 to 500.
"But I'm not allowed to make any forward-looking statements," he says, a curious rule, I always think, a bit like off-side in footie.
"I don't believe in one person becoming an inventor these days," he is saying. "It has to be a team now. We shall make some more acquisitions -- we have a list of targets, but nothing that's more than 10 per cent our size, and we're not interested in mergers."
I'm keen to find out why they took so long to float, and whether they thought about pulling it when the market went sick.
"We wanted to make sure we had proved the business model, and the city likes a track record. I didn't want to float on a dream," he says, and I start thinking about levitation again.
"I'm surprised there wasn't more comment about the way we bucked the trend this month, but, no, we never considered pulling it."
So what's his proudest achievement? Apparently it is none of the wondrous high tech or lifesciences inventions that have come out of the Mill, but the humble payphone.
Back in the mid '70s Plessey invited him up to Liverpool. They had been making the old mechanical telephone exchange from time immemorial but were soon to embark on the next generation. However, there was to be a production gap and it needed filling; Mr Edge was asked whether he had any ideas.
He did. The first digital payphone, the one you can see still, all over the world.
Is there anything else he would particularly like to do now? He shakes his head. I persist. "Write an opera," I stab in the dark. "I've done that," he says. "A bit of jazz, too." He, like Mike Lynch, plays the clarinet.
He's a bit like his business model, diverse, and as I say on the way out, there's always such comfort in that. But, the legend holds good, first aid beside the point.

[rambutan2] 03/9/2002 12:09

Below are a few bits and bobs which show the powerful backing Generics has.
Read on...

Ikeas reclusive founder and chairman Ingvar Kamprad has no intention of releasing his grip on his empire, to the dismay of many investment banks, salivating over the successful retail chain that attracts 140 million visitors every year.
A new book on Ikeas management and secretive, complex company structure by Swedish economist and journalist Stellan Bjork estimates the company would be worth up to 100 billion crowns ($12.62 billion) if listed on a stockexchange.
This makes Ikea one of the Europe's largest privately-owned companies, alongside Briton Richard Bransons Virgin Group and Swedish carton giant Tetra Pak, based in Switzerland.
"This (latest expansion) can be done without having shareholders breathing down the companys neck with demands for quick profits as Ikea is not listed on the bourse," Bjork said.
As a private company, Ikea is not obliged to publish full reports, which has made it difficult to value the company.
Its independence by staying private has also enabled the Kamprad empire to save millions of crowns in tax each year by splitting the group into companies spread across the world.
Ikea, with its head office in the Danish capital, Copenhagen, is made up of numerous registered legal entities ranging from the Netherlands to Curacao in the Netherlands Antilles so avoiding Sweden's high taxes.
Since 1980 Ikea has been owned by a Netherland-based charity, the Stichting Ingka Foundation, headed by 72-year-old Kamprad. This wasdesigned to prevent the company becoming victim to a takeover or split up after Kamprad's death.

And on...


From Forbes.com:

Kamprad cashes in

In our article about Ingvar Kamprad (Aug. 7 (which is my next snippet)), the master of the Ikea furniture retailing group, we noted Kamprad's desire to keep Ikea in private hands. "I feel many responsibilities . . . but I don't want to feel responsible to investors. Investors are too greedy," he said.

But that doesn't mean that he dislikes buying and selling stocks. Inter Ikea Group, one of his group's divisions, is heavily invested in blue chips. Through Stichting Catella, part of Inter Ikea, Kamprad owns 91% of Catella, a private equity investor in Stockholm. Catella owns 70% of Generics, a scientific consulting and licensing company founded in 1986 that's based in Cambridge, U.K.

On Nov. 16 Generics announced that it would float 30% of its shares on the London Stock Exchange at $3.05 a share, valuing the entire company at $327 million. The $98 million offering, managed by Merrill Lynch, is seven times oversubscribed. Catella will retain slightly more than 50% of Generics' stock.

It looks as if Kamprad, the occasional equitophobe, has made a smart private equity investment: Catella has invested just $7 million in Generics to date. It will show roughly a $160 million paper gain on this one deal-with more potential profitability down the road as Generics continues to develop.


The snippet below is from a good piece on IKEAs founder called The Billionaire Next Door

But when it comes to sheltering Ikea from Sweden's confiscatory taxes and death duties, Kamprad spares no expense. Look at the chart below. Like the Wallenbergs, Rausings and other rich Swedes, Kamprad has shrouded his business in an opaque collection of trusts and holding companies. In essence, Kamprad's empire has been parceled out among three holding entities: Ikea Group, Inter Ikea Group and Ikano Group.

Ikea Group controls all Ikea retail operations, except franchisees, and also owns most of the land on which its Ikea stores stand. Inter Ikea is the custodian of the group's intellectual property, including the Ikea brand. It has also accumulated hidden reserves to help fund expansion and create a cushion for economic downturns.

For its efforts, Inter Ikea receives a licensing fee of 3% of Ikea Group's annual turnover; last year this amounted to $255 million. Inter Ikea also has substantial real estate holdings plus an equity interest in the Generics Group, a successful high-tech incubator in Cambridge, U.K.

The third holding company, Ikano Group, controls Habitat, a home furnishing chain that Kamprad bought from his old friend Terence Conran for an undisclosed price in the early 1990s. Recently Kamprad transferred ownership of Habitat to his three sons, to give them business interests outside of Ikea. Also in the Ikano Group portfolio are investments in real estate development and financial services.

[rambutan2] 03/9/2002 00:11

Well, 2p rise in ask price and no sells so far. Couple of big buys and it'll leap up.

11:24:36   12p   7p   12p   4,791   £575   BUY O
10:15:28   12p   7p   12p   8,375   £1,005   BUY O
09:43:20   10.699p   7p   12p   9,345   £1,000   BUY O
09:27:04   10p           40,000   £4,000   DLY O
08:35:34   10p   7p   10p   9,500   £950   BUY O
08:29:48   10p   7p   10p   15,000   £1,500   BUY O

[rambutan2] 02/9/2002 23:32

And here's another one.

21 August 2002
Sulzer and Generics Collaborate
Sulzer Innotec, the central business unit for research and development of the Sulzer Corporation, has agreed on a collaboration with The Generics Group. Both partners want to co-operate in sales and marketing and further develop and exploit Sulzer Innotec's Intellectual Property Rights (IPR, e.g. patents).

The agreement establishes a framework within which Sulzer Innotec and Generics can identify IPR, principally within Sulzer Innotec, and co-operate in the exploitation process of that IPR with a view to strengthening Sulzer Innotec's market position. Where appropriate, Generics may also contribute IPR to the co-operation, if this benefits the exploitation process. Joint sales and marketing activities will strengthen the market position of both parties in the consulting market place.

Hans Walter Schläpfer, President of Sulzer Innotec, said: "Sulzer Innotec has and is generating IPR that, if successfully exploited, will have considerable value. We are confident we can achieve a better value with the help of Generics' extensive expertise in developing and commercialising IP".

Sulzer Innotec (based in Winterthur, Switzerland) has been the research and development centre for the Sulzer Corporation for over 50 years. Its client base includes not only the Divisions of Sulzer but also an increasing number of external customers, especially industrial manufacturers and OEMs in the energy, transport, chemical, process industry and medical technology sectors (in 2001, close to half of the customers were non-Sulzer companies ). Research and development (Contract R&D) as well as ventures projects, together with specialised technology and production services currently enable the company to achieve an annual order volume of some 43 million Swiss francs (2001). Sulzer Innotec employs approximately 165 highly qualified specialists in engineering and materials.

Generics, publicly traded in London and based in Harston, Cambridge UK, is a company providing a range of technology consulting, advisory and investment services. It has an international reputation for successfully commercialising emerging science and technology. Generics invests in and develops technologies that underpin the future of the widest range of industries. Its key areas of expertise include: engineering, technology-based business development, materials, telecommunications, life sciences, sensors and electronics. Generics' facilities include state-of-the-art laboratories and are located in Europe in Cambridge, Frankfurt, Zürich and Stockholm, and in Boston and Baltimore in the USA. Generics has over 300 employees, of which more than half are high-calibre technology professionals.

[rambutan2] 02/9/2002 23:22

Bored? Here's a recent press release to peruse.

Press release of 21 August:

Sensopad Technologies Ltd (Sensopad), a spin-out from The Generics Group, announces today three new licences for its patented technology to the following companies:
- Bosch-Siemens in Germany for a new range of domestic appliances
- Herga Electric in UK for switchgear systems in healthcare, bathroom and marine applications
- Schefenacker Australia for Australasian domestic appliances

Sensopad was spun-out from Generics in April 2001. The company aims to exploit proprietary non-contact measurement techniques, which it describes as 'mini-radar', through licensing, development and hardware supply. Initially Sensopad has focused on some specific applications in domestic appliances but is aggressively expanding into larger markets such as automotive, children's games, consumer electronics and industrial systems. The technology is likely to have significant impact in future electronic systems for a range of high volume products.

Further collaboration projects are underway with industrial partners in the UK, USA, Germany and Australia. The projects are likely to result in further development contracts and licences before the end of 2002. The company has, to date, secured approx. £1m of financing from Generics and InterIkea's International Technology Fund.

In line with expansion in to other markets, Sensopad recently announced the appointment of Dr Bruce Macaulay as Chairman and Dr Ian Collins as Non-Executive director. Bruce Macaulay has previously held the posts of the Vice President of Engineering & Technology with Honeywell and Director of Technology Strategy & Pre-development with BMW. Ian Collins was previously CEO of Synaptics UK, the human interface technology company.

Sensopad has an on-going recruitment drive and hopes to announce further appointments to the technical development team in the near future.

Given the technology's big volume potential in automotive and consumer electronics, Sensopad is expected to announce a tie-up with one of the big US chip producers this summer.

CEO of Sensopad, Mark Howard, said: "I'm very pleased about the signed licences and appointments – they represent some important milestones for us. I think we're all even more excited about the growing pipeline of projects and licenses - now that the markets are becoming aware of the massive potential for this technology."


---------------ends----------------
Notes for Editors:
1 The Generics Group is an integrated technology consulting, development and investment company, with an international reputation for successfully exploiting emerging science and technology for commercial markets.
2 Bosch-Siemens Hausgeraete GmbH is Europe's market leader in domestic appliances with brand names such as Bosch, Siemens and Neff.
3 Herga Electric Ltd. is based in Bury St. Edmunds, UK and is an established manufacturer of a wide range of switchgear and electrical systems.
4 Schefenacker Australia is part of the German Schefenacker Group a global tier 1 supplier of components and systems to the automotive industry.
5 Bruce Macualay has 25 years experience with the automotive industry. Previous posts include Vice President of Engineering and Technology for Honeywell and Director of Technology Strategy & Pre-development with BMW.


Contacts:
Mark Howard, CEO, [e-mail]
Tel: [phone] www.sensopad.com

[rambutan2] 02/9/2002 17:18

Makes me even more confident, after all, even at 9p thats still £50k by each of them. Hopefully will wake up some buyers tomorrow morning.

[the matrix] 02/9/2002 15:56

Director buying!! check out CRB!!

[tony14] 02/9/2002 15:46

RNS Number:6424A
Generics Group AG
02 September 2002



On the 2nd September 2002, Gunnar Rylander, director of the Generics Group AG,
informed the company that on the 30th August 2002 he has purchased additional
555,555 shares of CHF 0.10 each in Generics at 9 pence per share. His total
holding of CHF 0.10 shares now stands at 1, 218,055 shares.

On the 2nd September 2002, Johan Bjorklund, director of the Generics Group AG,
informed the company that on the 30th August 2002 he has purchased additional
555,555 shares of CHF 0.10 each in Generics at 9 pence per share. His total
holding of CHF 0.10 shares now stands at 560,255 shares.




This information is provided by RNS
The company news service from the London Stock Exchange
END

RDSUUUQPBUPPGAP

[maxwellsdemon] 02/9/2002 13:08

rambutan2,

It is number two on the leader board, at the moment, but still very little interest in this IP company. Here is a list of the PCT patent applications which appear under "Generics" own name. There are more under the names of the other companies in which Generics have an interest.




1. (WO 02/066965) ASSAY APPARATUS, ASSAY METHOD AND PROBE ARRAY FOR USE IN SAME
2. (WO 02/065693) DATA PROCESSING APPARATUS AND METHOD
3. (WO 02/064255) BIOCHIP ARRAY
4. (WO 02/056246) PROGRAMMABLE TAGS
5. (WO 02/055201) SAMPLE PROCESSING APPARATUS
6. (WO 02/052740) TIMING AID FOR ULTRA-WIDEBAND SYSTEM
7. (WO 02/45286) ACOUSTIC COMMUNICATION SYSTEM
8. (WO 02/45273) COMMUNICATION SYSTEM
9. (WO 02/45046) TRAFFIC MONITORING SYSTEM
10. (WO 02/32022) COMMUNICATIONS APPARATUS
11. (WO 02/19435) A SPIN FILTER AND A MEMORY USING SUCH A SPIN FILTER
12. (WO 02/13276) A MEMORY DEVICE AND A MEMORY ARRAY
13. (WO 01/78889) A METHOD OF FABRICATING CODED PARTICLES
14. (WO 01/73881) MIXED REACTANT FUEL CELLS WITH FLOW THROUGH POROUS ELECTRODES
15. (WO 01/73880) MIXED REACTANT FUEL CELLS
16. (WO 01/63791) TRANSMITTER AND RECEIVER CIRCUIT
17. (WO 01/53106) ANTI-COUNTERFEITING DEVICE
18. (WO 01/42865) MAN-MACHINE INTERFACE
19. (WO 01/36030) SAFETY DEVICE
20. (WO 01/34264) ACOUSTIC LOCATION SYSTEM
21. (WO 01/32957) MANUFACTURING METHOD AND APPARATUS
22. (WO 01/10065) ACOUSTIC COMMUNICATION SYSTEM
23. (WO 01/05072) SIGNALLING SYSTEM
24. (WO 01/05071) SIGNALLING SYSTEM
25. (WO 01/05069) SIGNALLING SYSTEM
26. (WO 00/77480) POSITION ENCODER
27. (WO 00/65299 ) POSITION SENSOR
28. (WO 00/48338) OPTICAL FREE SPACE SIGNALLING SYSTEM
29. (WO 00/32353) A POLISHING MACHINE AND METHOD
30. (WO 00/26713) EYE TRACKING SYSTEM
31. (WO 00/19174) MAGNETIC FLOW METER
32. (WO 99/67606) CHECK WEIGHING APPARATUS AND METHOD
33. (WO 99/59882) CONTAINER FOR CARBONATED BEVERAGES
34. (WO 99/41621) CIRCUIT BOARD ASSEMBLY INSPECTION
35. (WO 99/19691) POSITION SENSOR
36. (WO 99/18653 ) MOTOR CONTROL SYSTEM
37. (WO 99/03216 ) REBROADCASTING COMMUNICATION SYSTEM
38. (WO 98/58237) POSITION DETECTOR
39. (WO 98/54545) TRANSDUCER AND METHOD OF MANUFACTURE
40. (WO 98/44100) DISASSOCIATION OF INTERACTING MOLECULES
41. (WO 98/35328) SIGNALLING SYSTEM
42. (WO 98/32248) SIGNALLING SYSTEM
43. (WO 98/10869) METHODS OF ANALYSIS/SEPARATION
44. (WO 98/02573) DENATURATION OF DOUBLE­STRANDED NUCLEIC ACID
45. (WO 98/00562) DENATURATION OF DOUBLE­STRANDED NUCLEIC ACID
46. (WO 98/00921) APPARATUS AND METHOD FOR PROCESSING SIGNALS OBTAINED FROM A POSITION ENCODER
47. (WO 97/43445) DENATURATION OF DOUBLE­STRANDED NUCLEIC ACIDS
48. (WO 97/41219) ELECTRODE CAPTURE OF NUCLEIC ACID
49. (WO 97/19323) POSITION ENCODER
50. (WO 97/14935) POSITION ENCODER
51. (WO 97/08914) MONITORING AND/OR CONTROL SYSTEM
52. (WO 97/08293) RELEASE OF INTRACELLULAR MATERIAL
53. (WO 97/04338 ) IMPROVEMENTS RELATING TO MAGNETIC TAGS OF MARKERS
54. (WO 97/00155) METHOD AND APPARATUS FOR OPTICAL POLISHING

[rambutan2] 02/9/2002 01:10

Duplicate!

[rambutan2] 02/9/2002 01:07

Must admit, previously hadnt fully grasped the relationship between Catella and GEN. GEN was, and still is really, a subsidiary of Catella. Before the float they owned 80%, after 49%, which hasnt changed.
Catella dont appear to be quite your run-of-the-mill investment company and seem to have an unusual, long term investment philosophy.
IMHO i just cant see them letting GEN go bust, they would do their utmost to help out GEN. As to whether this might involve them taking it private again, I really dont know whether this could be a real possibility or not. But i would have thought it would definatley be a move of last resort, and well down the road from where we are at present.
Will be interesting to see how much interest in the shares this coming week and whether a mkt cap of only 2/3s its cash, and of just 1/3 its promising VC portfolio, never mind any value attached to its patents and its consultancy work, will be enough to drive the price back up and into the 20ps.

[games] 31/8/2002 00:25

QuantumBeam.......

Depending on the successful completion of those trials, Parkes said he anticipated receiving the first orders in Q1 or Q2 of 2003.

It is at that stage that the company expects to secure second round funding - of between $10m and $15m.



So around £5m from gen if they want to keep their % stake. I quite like gen and was watching the price slip recently but a sudden fall tends to send the odd bell ringing, may have a nosey around to see if anything else needs cash soon, as if no-one wants (institution) gen shares at this price, whats to say they would stump up towards some of gen's investments.

[rambutan2] 30/8/2002 17:16

Here are the rest of the day's trades, which were all buys, some of them look institutional size to me. So someone must like them at this price.

16:42:43   9p           756,604   £68,094   DLY O
16:37:33   10p           50,000   £5,000   DLY O
16:32:29   10p           30,000   £3,000   DLY O
16:30:23   9p           1,666,666   £150,000   DLY O
16:07:13   9p           1,666,665   £150,000   DLY O
16:00:08   9p           150,000   £13,500   DLY O
15:58:48   10p           40,000   £4,000   DLY O
15:14:15   9.5p   6p   10p   10,394   £987   BUY O
14:31:58   9.5p           20,000   £1,900   DLY O
13:19:24   9.5p   6p   10p   1,322   £126   BUY O
13:14:28   9p           150,000   £13,500   DLY O
12:35:17   10p   6p   10p   15,000   £1,500   BUY O
11:57:31   10p   6p   10p   9,800   £980   BUY O
11:12:10   9.5p           20,000   £1,900   DLY O
11:00:43   9p           54,688   £4,922   DLY O
10:12:06   10p   6p   10p   10,000   £1,000   BUY O
10:02:47   10p   6p   10p   6,000   £600   BUY O

Plus, worth having a look at

GENs main shareholder.

[rambutan2] 30/8/2002 11:30

Another large sell this morning? Times today confirmed that yesterday's drop was due to just the one seller who had taken shares at the time of the LSE float. So that rules out Catella, and I thought that the only other holder of over 3% was Merrill Lynch, and no RNS so far, so, on the number of shares sold yesterday and this morning, must have been someone with just under 3%. Wonder who it was, not that it really matters. MMs spread rather offputting it must be said, they might persuade in some more buyers if they raised the offer price a couple of pence. Anyone heard anything in any dark corridors re GEN?

09:34:59   10p   6p   10p   2,500   £250   BUY O
09:33:03   7p           300,000   £21,000   DLY O
09:32:53   7p           230,269   £16,119   DLY O
09:05:21   10p   6p   10p   9,750   £975   BUY O
08:55:45   8.957p   6p   10p   5,000   £448   BUY O
08:04:43   10p   6p   10p   5,050   £505   BUY O

[tony14] 30/8/2002 00:57

2*400k@6p trades look like a rollover, but 120k sell @7p when then the prevailing bid was 10p! The MM's certainly drive a hard bargain.

[calleva] 30/8/2002 00:48

Price manipulation - someone is going to make a killing. The fall is unjustified.

Selling like hot cakes!

[fast player] 30/8/2002 00:46

Let it go..

this going down into nothingness.

The market is always right....Something is behind this fall. And we will be the last to find out as usual.